Briacell Therapeutics is at the forefront of developing innovative immuno-oncology therapies aimed at transforming cancer treatment. Their lead candidate, Bria-IMT™, is a patented, off-the-shelf, cell-based immunotherapy specifically designed to activate the patient's immune system to target and destroy cancer cells, particularly in metastatic breast cancer (MBC). This therapy has received Fast Track designation from the FDA and is currently undergoing a pivotal Phase 3 clinical study, following promising results from a Phase 2 trial that demonstrated significant survival benefits in heavily pre-treated MBC patients. The therapy's unique mechanism allows it to selectively kill cancer cells while sparing healthy tissues, showcasing its potential for improved patient outcomes.

In addition to Bria-IMT™, Briacell is advancing its Bria-OTS™ platform, which offers personalized off-the-shelf immunotherapies. This platform is engineered to express multiple unique HLA types, enabling it to provide matched treatments for over 99% of patients through a simple saliva test. Bria-OTS™ is currently being evaluated in a Phase 1/2 clinical study targeting various cancers, including breast and prostate cancer. The development of Bria-OTS™ aims to streamline the process of personalized immunotherapy, making it faster and more cost-effective compared to traditional methods. With ongoing collaborations and a robust clinical pipeline, Briacell Therapeutics is positioned to make significant contributions to the field of cancer immunotherapy.

United States

BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) is a clinical-stage biotechnology company specializing in targeted immunotherapies for cancer. BriaCell achieved positive proof-of-concept in a Phase I/IIa clinical trial for Bria-IMT™ in patients with advanced breast cancer. BriaCell is conducting a Phase I/IIa clinical trial of Bria-IMT™ in combination with a PD-1 inhibitor, retifanlimab (provided by Incyte under a collaboration agreement). Additionally, BriaCell is developing Bria-OTS™, the first “off-the-shelf” personalized immunotherapy for advanced breast cancer.

Cancer

Briacell Therapeutics

Breast cancer

Bria-IMT™ (SV-BR-1-GM)

Biologics

<p class="font_8">The mechanism of action of Bria-IMT™ is currently under investigation. We hypothesize that Bria-IMT™ both indirectly and directly stimulates the body’s own cancer-fighting cells to attack and destroy breast cancer tumors. INDIRECTLY, Bria-IMT™ produces breast cancer “antigens” (proteins that are expressed in breast cancer cells) that are then recognized by the immune system, which can then recognize those same antigens in a patient’s breast cancer and attack the cancer. In addition, Bria-IMT™ appears to be able to DIRECTLY stimulate these cancer-fighting immune cells markedly, boosting the body’s response.</p>

Briacell Therapeutics

Company Details